Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? B Badgwell, JN Cormier, S Krishnan, J Yao, GA Staerkel, PJ...

The ultimate goal of my research is to discover factors that can be used in childhood cancer prevention efforts and targeted interventions to limit the adverse consequences of childhood cancer treatment.

Philip J Lupo Background: Relative to other pediatric cancers, survival for rhabdomyosarcoma has not improved in recent decades, suggesting the need to enhance risk stratification.

Apr 21, 2022 · Dr. Philip Lupo is a genetic epidemiologist and Director of the Epidemiology and Population Sciences Program in the Texas Children’s Cancer and Hematology Center. A key area of his research is focused on cancer risk in children with birth defects.

Oct 17, 2022 · Dr. Lupo is board certified by the American Board of Otolaryngology. His professional interests include comprehensive acoustic neuroma management, advancing the science of cochlear implantation, innovative rehabilitation of chronic ear disease and refining techniques in primary and revision stapedectomy.

Philip J Lupo 1 , Logan G Spector 2 Affiliations 1 Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas. [email protected].

He is a proud family man with over 30 years of proven tax and accounting experience. When he's not serving clients, you can find Joe watching his favorite sports teams and enjoying time with his wife, four children, and Luca; the family dog and his "favorite child". Favorite Quote: "Be quick, but don't hurry." - John Wooden.

Aug 1, 2019 · Objectives: To identify specific birth defect-childhood cancer (BD-CC) associations and characterize cancer risk in children by increasing number of nonchromosomal birth defects.